CRDF Q3 2022 Earnings — Cardiff Oncology, Inc. Revenue & Financial Results | Market Cap Arena

CRDFCardiff Oncology, Inc.

$133M

Q3 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$93,000+8.1% YoY

Gross Profit

$93,000100.0% margin

Operating Income

-$9M-9669.9% margin

Net Income

-$9M-9216.1% margin

EPS (Diluted)

$-0.19

QoQ Revenue Growth

+2.2%

Cash Flow

Operating Cash Flow

-$7M

Free Cash Flow

-$8M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$124M

Total Liabilities

$10M

Stockholders' Equity

$113M

Cash & Equivalents

$19M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$93,000	$86,000	+8.1%
Gross Profit	$93,000	$86,000	+8.1%
Operating Income	-$9M	-$7M	-28.5%
Net Income	-$9M	-$7M	-24.0%